Zobrazeno 1 - 10
of 70
pro vyhledávání: '"N P Denisenko"'
Autor:
A. S. Zhiryakova, N. P. Denisenko, A. V. Kryukov, K. A. Akmalova, S. N. Tuchkova, K. B. Mirzaev, D. A. Sychev
Publikováno v:
Безопасность и риск фармакотерапии, Vol 12, Iss 2, Pp 178-189 (2024)
INTRODUCTION. The variability in patient response to non-steroidal anti-inflammatory drugs (NSAIDs) may be due to genetic polymorphisms. Decreased-function or non-functional CYP2C9 alleles are known to be significant contributors to response variabil
Externí odkaz:
https://doaj.org/article/ce69b2b2c49b44658781ec122244b276
Autor:
D. A. Sychev, K. B. Mirzaev, M. S. Cherniaeva, N. V. Shakhgildyan, Sh. P. Abdullaev, N. P. Denisenko, Zh. A. Sozaeva, A. A. Kachanova, V. R. Shastina, S. V. Gorbatenkova
Publikováno v:
Acta Biomedica Scientifica, Vol 8, Iss 6, Pp 51-80 (2024)
Background. The use of P-glycoprotein (P-gp) inhibitors and carriage of certain ABCB1 polymorphisms can lead to increased concentrations of rivaroxaban and the development of bleeding.The aim of the study. To study the features of drug-drug interacti
Externí odkaz:
https://doaj.org/article/80ceb717f6c74d60a892134e49db667e
Autor:
Sh. P. Abdullaev, N. P. Denisenko, I. I. Temirbulatov, A. A. Kachanova, S. N. Tuchkova, E. V. Mikhaylenko, A. V. Kryukov, T. T. Valiev, K. B. Mirzaev, D. A. Sychev
Publikováno v:
Acta Biomedica Scientifica, Vol 8, Iss 6, Pp 23-30 (2024)
Background. There is a mounting evidence in the scientific literature that susceptibility to SARS-CoV-2 infection could vary. The severity of COVID-19 symptoms can range from asymptomatic to severe respiratory failure, requiring prolonged artificial
Externí odkaz:
https://doaj.org/article/7c25c2af93a1434da4254760586fc038
Autor:
S. Р. Abdullaev, К. М.-В. Mammaev, N. Р. Denisenko, I. l. Temirbulatov, A. А. Kachanova, E. V. Mikhaylenko, А. V. Kryukov, Т. Т. Valiev, К. В. Mirzaev, S. N. Mammaev, D. А. Sychev
Publikováno v:
Антибиотики и Химиотерапия, Vol 68, Iss 7-8, Pp 34-41 (2023)
Background. Previously, genetic markers rs11385942 G>GA and rs657152 C>A of disease severity were identified for COVID-19. The study of the prevalence of clinically significant genetic markers may be useful for the development of region-specific appr
Externí odkaz:
https://doaj.org/article/a75d65bdd43843fcab256dcd29d0c27a
Autor:
Yu. V. Shevchuk, A. V. Kryukov, I. I. Temirbulatov, I. V. Sychev, K. B. Mirzaev, N. P. Denisenko, Sh. P. Abdullaev, S. N. Tuchkova, V. I. Vechorko, O. V. Averkov, D. A. Sychev
Publikováno v:
Фармация и фармакология (Пятигорск), Vol 11, Iss 3, Pp 228-239 (2023)
Remdesivir is a drug widely used for the etiotropic treatment of COVID-19. According to a number of studies, the incidence of adverse reactions during remdesivir therapy reaches 66%, with the most common is an increase in liver function tests.The aim
Externí odkaz:
https://doaj.org/article/6b3b5a75901b45d09a94422a067614ef
Autor:
I. I. Temirbulatov, A. V. Kryukov, K. B. Mirzaev, N. P. Denisenko, S. P. Abdullaev, A. V. Petrova, E. P. Tkach, A. V. Shipacheva, D. A. Sychev
Publikováno v:
Антибиотики и Химиотерапия, Vol 68, Iss 5-6, Pp 55-61 (2023)
The aim of the study was to evaluate the associations of different variants of AOX1 and CYP1A2 genes with safety parameters of favipiravir therapy in patients with COVID-19. Material and Methods. The study included 86 patients hospitalized at Moscow
Externí odkaz:
https://doaj.org/article/74a0d8640e3b45ad87934a6e71cebedc
Autor:
I. V. Sychev, N. P. Denisenko, A. A. Kachanova, A. V. Lapshtaeva, Sh. P. Abdullaev, L. N. Goncharova, K. B. Mirzaev, D. A. Sychev
Publikováno v:
Безопасность и риск фармакотерапии, Vol 11, Iss 2, Pp 231-240 (2023)
Angiotensin-converting enzyme inhibitors (ACEIs) are among the most prescribed and effective medicinal products for the treatment of several cardiovascular diseases. According to a number of studies, 30% of patients taking ACEIs develop adverse drug
Externí odkaz:
https://doaj.org/article/612fe468ef6f4c729519954a14d7b41a
Autor:
A. V. Kryukov, A. S. Zhiryakova, Yu. V. Shevchuk, A. V. Matveev, V. I. Vechorko, O. V. Averkov, S. V. Glagolev, I. I. Temirbulatov, K. B. Mirzaev, N. P. Denisenko, Sh. P. Abdullaev, D. A. Sychev
Publikováno v:
Безопасность и риск фармакотерапии, Vol 10, Iss 4, Pp 326-344 (2022)
The safety of COVID-19 pharmacotherapy is a relevant issue, first of all, because of the current lack of experience with using particular medicinal products and with off-label prescribing. The aim of the study was to analyse information on potential
Externí odkaz:
https://doaj.org/article/5d9ff01bf50b46dfb11a1965a596882f
Autor:
I. I. TEMIRBULATOV, A. V. KRYUKOV, K. B. MIRZAEV, N. P. DENISENKO, S. P. ABDULLAEV, A. S. ZHIRYAKOVA, Y. V. SHEVCHUK, V. I. VECHORKO, O. V. AVERKOV, D. A. SYCHEV
Publikováno v:
Антибиотики и Химиотерапия, Vol 67, Iss 7-8, Pp 45-50 (2022)
The aim of the study was to assess the association of polymorphic variants CYP3A5*3 6986 A>G rs776746 and CYP3A4*22 rs35599367 C>T with the safety parameters of remdesivir therapy in patients with COVID-19.Material and methods. The study included 156
Externí odkaz:
https://doaj.org/article/529d41e696844e8bbf54c26567f38e08
Autor:
N. P. Denisenko, Sh. P. Abdullaev, K. A. Akmalova, Zh. A. Sozaeva, A. A. Kachanova, M. S-Kh. Sozaeva, L. Z. Bolieva, E. A. Grishina, D. A. Sychev
Publikováno v:
Современная ревматология, Vol 16, Iss 1, Pp 60-67 (2022)
The efficacy and safety of non-steroidal anti-inflammatory drugs (NSAIDs) may be determined by the polymorphic nature of the CYP2C8, PTGS1 and PTGS2 genes.Objective: to analyze the nature of the distribution of CYP2C8*3 (rs10509681), CYP2C8*3 (rs1157
Externí odkaz:
https://doaj.org/article/e05ca74d86d449cba880c648b464c477